Follows children with fatty liver disease across European centres over time
Records the long-term course of fatty liver disease in children under 18.
Key facts
- Who runs it
- Cambridge University Hospitals NHS Foundation Trust
- Where
- Birmingham and Cambridge, United KingdomSee the 2 sitesAlso in 1 other country, 1 site
- Trial code
- Registry title
- European Paediatric Non-Alcoholic Fatty Liver Disease Registry (EU-PNAFLD)
- Status
- Recruiting
- People taking part
- 2,000 people, planned
- Started
- 14 Nov 2017
- Expected to end
- Nov 2047
- Type of study
- Observational
- Record updated
- 4 March 2022
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The registry is looking for children whose non-alcoholic fatty liver disease (NAFLD) was diagnosed before the age of 18. It follows them over time.
- Age
- Diagnosed under 18 years of age; maximum age 18 Years
- Sex
- Boys and girls can both join
- Disease stage
- Any stage of NAFLD: simple fatty liver, fatty liver with abnormal liver blood tests (transaminases), NASH with or without scarring (fibrosis) or cirrhosis
- Biomarker or test result
- Fat in the liver seen on imaging (for example increased echogenicity on ultrasound), with other causes ruled out by tests. A liver biopsy (histology) may also be used.
Main reasons for not taking part
- Fatty liver caused by another disease (for example glycogen storage disease, Wilson disease, viral hepatitis, autoimmune hepatitis, type 1 diabetes mellitus)
- Fatty liver caused by drugs
- Fatty liver after a transplant
- More than 20g/day of ethanol (alcohol) intake
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Diagnosis made under 18 years of age
- Diagnosis of NAFLD spectrum disease (simple steatosis (NAFL), steatosis with abnormal transaminases, NASH ± fibrosis or cirrhosis)
- Diagnosis established by:; Radiological evidence of hepatic steatosis (e.g. increased hepatic echogenicity on ultrasound), with; Exclusion of secondary causes (negative serological liver screen for HBV/HCV, caeruloplasmin >0.20g/L, no history of excess alcohol consumption, no evidence of iron overload, and no clinically significant alpha-1 antitrypsin (A1AT) phenotype (i.e. SZ, ZZ, SS), with or without; Histology (>5% steatosis and histology consistent with paediatric NAFLD)
Who cannot take part
- Post-transplant fatty liver
- Secondary fatty liver disease (e.g. glycogen storage diseases, Wilson disease, viral hepatitis, drug-related, autoimmune hepatitis, type 1 diabetes mellitus)
- >20g/day ethanol intake
Where in United Kingdom
Also in 1 other country, 1 site
- Birmingham Children's HospitalBirmingham, United KingdomContact: Indra van MourikTaking people
- Addenbrooke's HospitalCambridge, United KingdomContact: Jake P MannTaking people
About the trial
What the trial wants to find out
The EU-PNAFLD (The European Paediatric NALFD Registry) will be a network composed of European centres involved in the care of children with NAFLD, and will include Hepatologists, Endocrinologists, and Scientists, supported by relevant international specialists. This collaboration will build on existing infrastructure (local databases and bio-repositories) and will align with the adult European NAFLD Registry ("EPoS", Elucidating Pathways of Steatohepatitis study) to allow long-term follow-up supported by translational studies. Through an international, well-characterised large-scale cohort, we hope to: facilitate multi-centre clinical trials; extend our understanding of the key disease mechanisms of NAFLD; and establish the natural history of paediatric NAFLD.
The group in the trial
- Non-alcoholic fatty liver disease patients
Children (\<18 years) with a diagnosis of NAFLD with radiological demonstration of increased liver fat and exclusion of other causes.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- The European Paediatric Non-alcoholic Fatty Liver Disease Registry (EU-PNAFLD): a Prospective, Longitudinal Follow-up of Children With Non-alcoholic Fatty Liver Disease
- Plain-language title
- Follows children with fatty liver disease across European centres over timeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 4 March 2022